Table 1 Basic characteristics of included systematic reviews on adverse events by drug or biologics
Basic characteristics | No. of systematic reviews (N = 279) |
|---|---|
Region of the corresponding author | |
Africa | 14 (5.02%) |
America (North and South) | 62 (22.22%) |
Asia | 117 (41.94%) |
Europe | 82 (29.39%) |
Oceania | 4 (1.43%) |
Type of meta-analysis | |
Pairwise meta-analysis | 241 (86.38%) |
Network meta-analysis | 38 (13.62%) |
The number of trials included | 16 (IQR: 10 to 32) |
1 to 9 (minimum is 3) | 69 (24.73%) |
10 to 29 | 135 (48.39%) |
30 or more (maximum is 597) | 75 (26.88%) |
Protocol | |
Yes | 77 (27.60%) |
No | 202 (72.40%) |
Topic of disease | |
Cancer | 113 (40.50%) |
Diabetes | 29 (10.39%) |
Osteoarticular diseases | 25 (8.96%) |
Cardiovascular diseases | 16 (5.73%) |
Mental disorders | 12 (4.30%) |
Inflammatory bowel disease | 10 (3.58%) |
Respiratory diseases | 9 (3.23%) |
Blood and lymphatic system diseases | 8 (2.87%) |
Neuropathy diseases | 7 (2.51%) |
Coagulation and anticoagulation | 6 (2.15%) |
HCV/HIV/HPV | 6 (2.15%) |
Autoimmune diseases | 5 (1.79%) |
Infection | 5 (1.79%) |
Neuropathy diseases | 5 (1.79%) |
Addition | 4 (1.43%) |
Lower urinary tract symptoms | 3 (1.08%) |
Inflammation | 3 (1.08%) |
Others | 13 (4.66%) |
Funding | |
No funding | 94 (33.69%) |
Not reported | 85 (30.47%) |
Non-profit funding | 94 (33.69%) |
For profit funding | 6 (2.15%) |